SNY - Sanofi

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Show:
Annual

Income statement

Currency in EUR. All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
45,389,000
45,389,000
39,175,000
37,369,000
37,631,000
Cost of revenue
13,695,000
13,695,000
12,255,000
12,157,000
11,976,000
Gross profit
31,694,000
31,694,000
26,920,000
25,212,000
25,655,000
Operating expenses
Research development
6,706,000
6,706,000
5,692,000
5,529,000
6,018,000
Selling general and administrative
10,492,000
10,492,000
9,555,000
9,390,000
9,883,000
Total operating expenses
19,813,000
19,813,000
17,773,000
17,319,000
18,429,000
Operating income or loss
11,881,000
11,881,000
9,147,000
7,893,000
7,226,000
Interest expense
472,000
440,000
368,000
390,000
444,000
Total other income/expenses net
-1,228,000
-3,379,000
-1,021,000
6,248,000
-4,101,000
Income before tax
10,422,000
8,268,000
7,798,000
13,804,000
2,822,000
Income tax expense
2,006,000
1,503,000
1,558,000
1,813,000
139,000
Income from continuing operations
8,484,000
6,833,000
6,279,000
12,350,000
2,938,000
Net income
8,371,000
6,720,000
6,223,000
12,314,000
2,806,000
Net income available to common shareholders
8,371,000
6,720,000
6,223,000
12,314,000
2,806,000
Basic EPS
-
3.35
2.48
4.91
1.10
Diluted EPS
-
3.33
2.48
4.88
1.09
Basic average shares
-
2,503,800
2,505,000
2,507,200
2,499,800
Diluted average shares
-
2,513,800
2,515,800
2,520,200
2,514,200
EBITDA
-
10,761,000
9,746,000
15,875,000
5,412,000